From time to time, WW will spotlight clinical trials in the WM Clinical Trials Network (WM-Net). WM-Net is a multi-institutional network for clinical and research programs dedicated to WM. In this issue, we are spotlighting a study examining the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). Shayna Sarosiek, MD, Dana-Farber Cancer Institute, is the principal investigator.
This is a single-arm, open-label, phase II study to evaluate the safety and efficacy of loncastuximab tesirine in patients with Waldenström Macroglobulinemia (WM) who have received at least 2 prior treatments, including an anti-CD20 antibody such as rituximab and a BTK inhibitor such as ibrutinib.
The U.S. Food and Drug Administration (FDA) has not approved loncastuximab tesirine for Macroglobulinemia (WM) but it has been approved for other uses. Loncastuximab tesirine is a type of therapy called an antibody-drug conjugate. This type of treatment is an antibody to CD19, a protein that is typically found on B-cells and plasma cells in patients with Macroglobulinemia (WM). This is a targeted therapy that uses an antibody (immunoglobulin) to deliver a toxin directly to the cancer.
The research study procedures include screening for eligibility and study treatment including evaluations and follow-up visits.
It is expected that about 36 people will take part in this research study.
ADC Therapeutics is supporting this research study by providing funding and the study drug.
If you are interested in learning more about clinical trials and how you might participate, please visit https://iwmf.com/clinical-trials/
Please click below to see more information regarding this trial:
https://classic.clinicaltrials.gov/ct2/show/NCT05190705